Table I.
Clinicopathological and prognostic impacts of Notch signaling pathway members in patients with NSCLC.
| Clinicopathological parameters | Prognosis | |||||
|---|---|---|---|---|---|---|
| Notch pathway member | Tumor size | Lymph node metastasis | NSCLC | Adenocarcinoma | Squamous cell carcinoma | (Refs.) |
| Notch1 | Na | OSb | NS | NS | (21) | |
| Notch3 | NS | Na | OSb | OSb | NS | (21) |
| DLL4 | OSb | OSb | OSb | (21) | ||
| DLL1 | NS | (21) | ||||
| DLL3 | NS | (21) | ||||
| Hes1 | OSb | OSb | OSb | (21) | ||
| Notch4 | NS | 5-year SRb | NS | NS | (16) | |
| Stromal Notch4 | NS | Nb | 5-year SRa | NS | 5-year SRa | (16) |
| Jagged1 | NS | NS | NS | NS | (16) | |
| Stromal Jagged1 | NS | 5-year SRa | NS | 5-year SRa | (16) | |
| Stromal DLL4 | NS | 5-year SRa | NS | 5-year SRa | (16) | |
| Activated Notch1 | 5-year SR (p53-negative group)b | (15) | ||||
a
Positively associated
b
negatively associated. N, lymph node; NSCLC, non-small cell lung carcinoma; NS, not significant; OS, overall survival rate; DLL, delta-like ligand; Hes1, Hes family BHLH transcription factor 1; SR, survival rate.